Exploring Resistance Exercise Training Plus High-Intensity Interval Training (ReHIIT) as Cancer Prehabilitation

NCT07313332 | Not Yet Recruiting

• 1 other identifier: FMHS 237-0925
• Study Type: interventional
• Target: 14
• Locations: 1 country
• Sites: 1

Brief Summary

Colorectal cancer is the fourth most common cancer in the UK. Prehabilitation, including exercise, can improve recovery from surgery. This pilot study investigates the combined effects of resistance and high-intensity interval training (ReHIIT) in healthy adults to establish baseline physiology and responses for comparison with cancer patients

Conditions

Healthy Adult Male and Female Volunteers; Intervention

Outcome Measures

Primary Outcomes (2)

• Change in anaerobic threshold (CPET-derived)

  From baseline to 4-weeks after the start of the intervention

• Change in Muscle mass

  Derived from DXA and stable isotope assessments of muscle mass (COSIAM, Cegielski et al., 2021)

  From baseline to 4-weeks after the start of the intervention

Study Arms (1)

Resistance exercise training plus high-intensity interval training (ReHIIT) Intervention

EXPERIMENTAL

Participants will complete 8-12 supervised sessions combining high-intensity interval cycling and resistance training at 70% 1-RM.

Other: ReHIIT Training Intervention

Interventions

ReHIIT Training Intervention OTHER

Participants will complete 8-12 supervised sessions combining high-intensity interval cycling (5 × 1-minute intervals at 110% CPET wattage, with 90-second rest intervals) and resistance training at 70% 1-RM (3 sets of 8-12 repetitions, 6 exercises).

Resistance exercise training plus high-intensity interval training (ReHIIT) Intervention

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Participant is willing and able to give informed consent for participation in the study.
• Availability and willingness to attend the Royal Derby Hospital site for a minimum of 8 exercise sessions and 2 assessment sessions across the study period.

You may not qualify if:

• BMI \<18 or \>35 kg/m2
• Known active cance
• Known metabolic disease
• Current known neurological or musculoskeletal conditions (e.g. epilepsy)
• Active known cardiovascular, cerebrovascular or respiratory disease - e.g:
• Uncontrolled hypertension (systolic BP \> 160 mmHg or diastolic BP \>100 mmhg)
• Myocardial infarction within the last 6 months or unstable angina
• Heart failure (New York Heart association Class III/IV)
• Arrhythmia
• Right to left cardiac shunt
• Aneurysm of a named blood vessel
• COPD
• Pulmonary hypertension
• Exercise-induced or brittle asthma
• Previous stroke/transient ischaemic attack

Sponsors & Collaborators

• University of Nottingham: lead

Study Sites (1)

Medical School, University of Nottingham, Royal Derby Hospital

Derby, Derbyshire, DE223DT, United Kingdom

Location

Study Officials

• Professor Bethan E Phillips

  University of Nottingham

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Tyler J Daubrah-Scott, MRes, BSc (Hons)

CONTACT

01332 724676; tyler.daubrah-scott@nottingham.ac.uk

Wayne Fradley, BMBS (hons) MRCS (2022)

CONTACT

01332 724640; wayne.fradley@nottingham.ac.uk

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Model Details: Participants will complete 8-12 supervised sessions combining high-intensity interval cycling and resistance training (three sets of 8 reps @ \~70% 1-RM across 6 exercises (3 upper-body, 3 lower-body)).

Study Record Dates

• First Submitted: November 28, 2025
• First Posted: December 31, 2025
• Study Start: January 1, 2026
• Primary Completion (Estimated): December 1, 2027
• Study Completion (Estimated): December 1, 2027
• Last Updated: December 31, 2025

Record last verified: 2025-10

Locations

GB (1)